Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aticaprant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 known ✓ | P41145 | 20/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 16/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 12/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aticaprant SCHEMBL29940327 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1 | |
| Aticaprant SCHEMBL29425177 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1 | |
| Aticaprant SCHEMBL2638130 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1 | |
| Aticaprant SCHEMBL2638855 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1 | |
| SCHEMBL26214372 | 0.92 | OPRK1 (0.85) | OPRK1OPRM1OPRD1 | |
| SCHEMBL26214370 | 0.92 | OPRK1 (0.85) | OPRK1OPRM1OPRD1 | |
| SCHEMBL26214364 | 0.92 | OPRK1 (0.85) | OPRK1OPRM1OPRD1 | |
| SCHEMBL25401006 | 0.92 | OPRK1 (0.84) | OPRK1OPRM1OPRD1 | |
| SCHEMBL30569965 | 0.92 | OPRK1 (0.84) | OPRK1OPRM1OPRD1 | |
| SCHEMBL26308195 | 0.92 | OPRK1 (0.84) | OPRK1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238245-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION | Janssen Pharmaceuticals, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20240238245-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION | Janssen Pharmaceuticals, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20230348377-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. | 2023-11-02 | — | — | US | disclosed |
| US-20230348377-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. | 2023-11-02 | — | — | US | disclosed |
| WO-2023170547-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023170550-A1 | POLYMORPH FORMS OF ATICAPRANT FOR USE IN TREATING MAJOR DEPRESSIVE DISORDER | Janssen Pharmaceuticals, Inc. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023170554-A1 | COMPOSITIONS COMPRISING ATICAPRANT | Janssen Pharmaceuticals, Inc. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230277499-A1 | FORMS OF ATICAPRANT | Janssen Pharmaceuticals, Inc. | 2023-09-07 | — | — | US | disclosed |
| US-20230277500-A1 | COMPOSITIONS COMPRISING ATICAPRANT | Janssen Pharmaceuticals, Inc. | 2023-09-07 | — | — | US | disclosed |
| US-20230233525-A1 | Compositions And Methods For The Treatment Of Depression | JANSSEN PHARMACEUTICALS INC (US) | 2023-07-27 | — | — | US | disclosed |
| EP-2252581-B1 | KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST | LILLY CO ELI (US) | 2012-06-20 | — | — | EP | disclosed |
| US-8173695-B2 | Kappa selective opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173695-B2 | Kappa selective opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100197669-A1 | KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197669-A1 | KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2010-08-05 | — | — | US | disclosed |
| US-7709522-B2 | Kappa selective opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709522-B2 | Kappa selective opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2010-05-04 | — | — | US | disclosed |
| WO-2009094260-A1 | KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2009-07-30 | — | — | WO | disclosed |
| US-20090186873-A1 | KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY | 2009-07-23 | — | — | US | disclosed |
| US-20090186873-A1 | KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186873-A1 | KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885OPRM1 3/4885OPRD1 2/4885 |
| US-20230277499-A1 | FORMS OF ATICAPRANT | ATIC, ADORA1, ADORA2A | OPRK1 1448/4885OPRM1 2120/4885OPRD1 1285/4885 |
| US-20230233525-A1 | Compositions And Methods For The Treatment Of Depression | SLC6A2, SLC6A4, HTR5A | OPRK1 367/4885OPRM1 712/4885OPRD1 621/4885 |
| US-20230277500-A1 | COMPOSITIONS COMPRISING ATICAPRANT | ADORA1, ADORA2B, ADORA2A | OPRK1 208/4885OPRM1 504/4885OPRD1 420/4885 |
| US-20240238245-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION | SLC6A2, SLC6A4, HTR5A | OPRK1 367/4885OPRM1 712/4885OPRD1 621/4885 |
| US-20230348377-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | ATIC, ADORA1, ADORA2A | OPRK1 1387/4885OPRM1 1523/4885OPRD1 952/4885 |
| US-20100197669-A1 | KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885OPRM1 3/4885OPRD1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.